Caledonia Investments (Australia)’s Royalty Pharma RPRX Stock Holding History

Caledonia Investments (Australia)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$324M	Sell	5,775,851 -1,392,548	-19%	-$72.5M	11.06%	4
2026 Q1	$344M	Sell	7,168,399 -208,639	-3%	-$9.14M	10%	5
2025 Q4	$285M	Sell	7,377,038 -170,571	-2%	-$6.5M	5.46%	5
2025 Q3	$266M	Buy	7,547,609 +1,102,880	+17%	+$39.9M	4.33%	5
2025 Q2	$232M	Buy	6,444,729 +1,330,162	+26%	+$44.1M	3.69%	5
2025 Q1	$159M	Buy	+5,114,567	New	+$162M	2.59%	7

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caledonia Investments (Australia)'s RPRX Position: Q2 2026 in Review

Caledonia Investments (Australia) reduced its Royalty Pharma (RPRX) stake by 19% in Q2 2026, selling an estimated $72.5M and leaving 5,775,851 shares worth $324M. The position accounts for 11.06% of the portfolio, ranked #4.

Caledonia Investments (Australia) first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $344M in Q1 2026. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Caledonia Investments (Australia) held 5,775,851 shares of Royalty Pharma worth $324M as of Q2 2026.
Caledonia Investments (Australia) sold 1,392,548 Royalty Pharma shares in Q2 2026, an estimated $72.5M.
Royalty Pharma made up 11.06% of Caledonia Investments (Australia)'s portfolio in Q2 2026, its #4 holding.
Caledonia Investments (Australia) first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
Caledonia Investments (Australia)'s Royalty Pharma position peaked at $344M in Q1 2026.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Caledonia Investments (Australia)'s 13F filing for Q2 2026, filed 14 Aug 2026.